George Budwell

George Budwell


George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Recent articles

Is Aphria a Buy?

Aphria is the cheapest pot producer in all of Canada by a wide margin.

3 Top Biotech Stocks to Buy Right Now

These three biotech stocks should turn out to be outstanding long-term growth vehicles.

Better Buy: AbbVie vs. Pfizer

AbbVie and Pfizer are both undergoing a radical makeover. Which company should investors trust to come out even stronger?

Is Tilray Finally a Buy?

Is Tilray's strong first-quarter report a good reason to buy this flagging pot stock?